Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
NCT02736955Phase 3Completed
- Lead sponsor
- Neurocrine Biosciences (Industry)
- Enrollment
- 161 (actual)
- Start date
- 13 Jun 2016
- Primary completion
- 30 Jun 2017 (actual)
- Study completion
- 30 Jun 2017
- Last update posted
- 19 Dec 2018
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Valbenazine Drug
Conditions and primary outcome
- Tardive Dyskinesia
Primary outcome
Number of Participants Monitored for Long-term Safety of Valbenazine (60 weeks)
Posted results on ClinicalTrials.gov
Source: ClinicalTrials.gov results for NCT02736955 (opens in a new tab)· Licence: public-domain
First posted · Last update posted · Imported from ClinicalTrials.gov download 2026-10-25
Primary outcomes with a statistical analysis
No primary outcome with a statistical analysis is posted for this study.
Serious adverse events
Time frame: Up to 60 weeks
| Group | Affected | At risk |
|---|---|---|
| Valbenazine 40 mg | 3 | 35 |
| Valbenazine 80 mg | 11 | 117 |
| Valbenazine 40/80 mg | 2 | 8 |
Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedA long-term, open-label study of valbenazine for tardive dyskinesia.
CNS spectrums · 2021 Aug
PubMed 32419679 (opens in a new tab)DOI 10.1017/S109285292000108X (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT02736955 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.